ABOUT THIS PODCAST 🔗

Update frequency:
every 39 days
Average audio length:
42 minutes
English
United States
9 episodes
since Sept. 7, 2020
episodic

LATEST EPISODE 🔗

Critical Care Reviews’ Rob Mac Sweeney talks with Prof. Alistair Nichol about ivermectin, one of the latest interventions added to the REMAP-CAP trial. He explains why this intervention is implemented into the trial despite the controversy surrounding the use of ivermectin to treat COVID-19. 

SEARCH PAST EPISODES

Search past episodes of REMAP-CAP.

PREVIOUS EPISODES

Critical Care Reviews’ Rob Mac Sweeney talks with  Dr. Lennie Derde about her background in critical care, infectious diseases and research, all the output generated by REMAP-CAP so far and her view on how this pandemic is likely to progress.
Critical Care Reviews’ Rob Mac Sweeney talks with professor Derek Angus about the interaction between clinical research and clinical practice.
Critical Care Reviews’ Rob Mac Sweeney talks with professor Alistair Nichol about the new Ventilation domain of REMAP-CAP.
Critical Care Reviews’ Rob Mac Sweeney talks with professor Mathias Pletz about pandemics and the COVID-19 pandemic mode of REMAP-CAP.
Critical Care Reviews’ Rob Mac Sweeney talks with Dr. Scott Berry about the statistical plan of REMAP-CAP.
Critical Care Reviews’ Rob Mac Sweeney talks with professor John Marshall and assistant professor Srinivas Murthy about the interventions in REMAP-CAP.
Critical Care Reviews’ Rob Mac Sweeney talks with professor Steve Webb about the design of REMAP-CAP. In this episode we describe the rationale behind the trial and its origin.
Together with Derek Angus and Tony Gordon, Rob Mac Sweeney dives into the first results of the REMAP-CAP trial and the launch of the first manuscript in JAMA. In this episode we discuss the methodology of the trial and the results of this manuscript.
You have seen all episodes of this podcast
Disclaimer: The podcast and artwork embedded on this page are from REMAP-CAP, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.